Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. 10-K, Item 1

Headquarters
Boston, MA
CEO
Christopher Simon
Next results
around Feb 4, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2026

Revenue of $1.3B through the costs to a net profit of $97.3M · income statement of the 10-K

12% operating margin
Revenue to Gross profit: $787.6MRevenue to Cost of revenue: $546.4MGross profit to Operating profit: $156.7MGross profit to Operating expenses: $630.9MOperating profit to Net profit: $97.3MOperating profit to Tax & other: $59.4MOperating expenses to R&D: $59.8MOperating expenses to Sales, admin & other: $571.1M Revenue: $1.3B REVENUE $1.3B −2% Y/Y Gross profit: $787.6M · 59% margin GROSS PROFIT $787.6M 59% margin · +5% Y/Y Cost of revenue: $546.4M · 41% of revenue COST OF REVENUE $546.4M 41% of revenue Operating profit: $156.7M · 12% margin OPERATING PROFIT $156.7M 12% margin · −29% Y/Y Operating expenses: $630.9M · 47% of revenue OPERATING EXPENSES $630.9M 47% of revenue Net profit: $97.3M · 7% margin NET PROFIT $97.3M 7% margin · −42% Y/Y Tax & other: $59.4M · 4% of revenue TAX & OTHER $59.4M 4% of revenue R&D: $59.8M · 4% of revenue R&D $59.8M 4% of revenue Sales, admin & other: $571.1M · 43% of revenue SALES, ADMIN & OTHER $571.1M 43% of revenue
Gross profit $787.6M 59% margin · +5% Y/Y
Operating profit $156.7M 12% margin · −29% Y/Y
Net profit $97.3M 7% margin · −42% Y/Y
The full income statement, year by year

HAE among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: -2.0%, above 8% of 154 peers (their median 10.5%) REVENUE GROWTH -2.0% · above 8% Gross margin: 59.6%, above 44% of 107 peers (their median 63.8%) GROSS MARGIN 59.6% · above 44% Operating margin: 12.8%, above 60% of 138 peers (their median 9.8%) OPERATING MARGIN 12.8% · above 60% Net margin: 7.5%, above 53% of 153 peers (their median 6.7%) NET MARGIN 7.5% · above 53% FCF margin: 21.6%, above 81% of 144 peers (their median 9.9%) FCF MARGIN 21.6% · above 81% Return on capital: 5.9%, above 25% of 89 peers (their median 9.2%) RETURN ON CAPITAL 5.9% · above 25%
HAE Peer median Below the median

What changed

4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed May 20, 2026 against May 21, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Valuation of goodwill (“As described in Note 10 to the consolidated financial statements, the Company had approximately $656 million of goodwill allocated among its reporting units as of March 28, 2026. The Company performs its annual impairment analysis as of the first day of the fourth quarter, and more frequently if the”). Same as last year: Business combination
  • Receivables +7.0% ($202.7M to $216.9M) vs revenue -2.0% ($1.4B to $1.3B), +9.0 pts apart
9 more checks with nothing to note
  • Cash from operations $293.2M vs net income $97.3M (FY ending Mar 28, 2026)
  • Inventory -16.1% ($365.1M to $306.4M) vs revenue -2.0% ($1.4B to $1.3B), -14.1 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

4 paragraphs in Risk Factors that were not in the 10-K filed May 21, 2025. Quoted as filed.

All 4 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed May 21, 2025 10-K, ITEM 1A
    An inability to successfully manage the implementation of our new global enterprise resource planning system could adversely affect our operations and operating results. We are in the process of implementing a new global enterprise resource planning system. This system will replace many of our existing operating and financial systems.…
  2. Item 1A · new paragraph · not in the 10-K filed May 21, 2025 10-K, ITEM 1A
    Additionally, FDA and foreign regulations and guidance are often revised or reinterpreted by the FDA and foreign counterparts in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of…
  3. Item 1A · new paragraph · not in the 10-K filed May 21, 2025 10-K, ITEM 1A
    The One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. on July 4, 2025. The OBBBA legislation provides for the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act of 2017, revisions to the international tax framework and the reinstatement of favorable tax treatment for certain business provisions.…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2023FY2024FY2025FY2026
Revenue$1.2B$1.3B$1.4B$1.3B
Net income$115.4M$117.6M$167.7M$97.3M
Operating cash flow$273.1M$181.8M$181.7M$293.2M
Free cash flow$81.7M$143.6M$142.4M$260.4M

Revenue, FY2017 to FY2026

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.3B ▼ 2.0% in FY2026

FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Haemonetics Corp, Boston, MA · from the 10-K filed May 20, 2026

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation.

Headquarters
Boston, MA
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
April 3
Last results
Nov 5, 2026
Incorporated in
MA

Email alerts

Sources

The 10-K filed May 20, 2026 (open at SEC), compared with the 10-K filed May 21, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.